Here is the synopsis of our sample research paper on Why EMI and Glaxo Achieved Such Different Results in the Medical Industry Despite High Levels of Innovation. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
During the 1970's EMI and Glaxo made leaps forward with innovative products; EMI and the CAT scanner and Glaxo with Zantac. Despite the levels of innovation only one firm succeeded; EMI failed while Glaxo succeeded, This 4 page paper considers why and how the differences in performance that led to this outcome arose. The bibliography cites 2 sources.
Page Count:
4 pages (~225 words per page)
File: TS14_TEEMIglaxo.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
to have very different results. The difference in performance can be attributed to a large number of potential influences, form internal influences such as management style, market focus, leverage of
resources, the use of intellectual capital as well as more practical aspects such as operations management,. There are also external influences, which may include competitive forces, economic influences, the social
environment as well as the development and use of technology to name a few,. These may also impact on the way a firm performance though their direct influences well as
the way that the firm chooses to respond to these macro-environmental factors. Where firms are compared and difference are seen, especially when looking at why some firms succeed while others
fail there will usually be a combination of influences rather than being able to put the difference down to a single factor. Even if it appears that there is a
fairly simple differentiating factor that can be blamed. A good example of this is the medical industry and the companies of EMI and Glaxo during the 1970s. EMI ad Glaxo
were in a very similar position, both were heavily reliant on being able to access the US medical market in order for their developments to be a commercial success. One
area of criticism that is often seen where companies fail is the failure to invest in research and development. This was not the case with EMI and Glaxo, both companies
were committed to investing in research and development (Black, 1997). It appears that both were aware to succeed in the medical industry there was not only the need for good
commercial pratices, but the requirement to develop new products. This was the strategy followed by other companies, The development of the two companies were very different, and in looking
...